Q9HCN6 (GPVI_HUMAN) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 101.
History...
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Platelet glycoprotein VI Short name=GPVI Alternative name(s): Glycoprotein 6 | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) [Reference proteome] | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo![]() |
Protein attributes
| Sequence length | 339 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | Collagen receptor involved in collagen-induced platelet adhesion and activation. Plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcR gamma-chain, the Src kinases (likely Fyn/Lyn), the adapter protein LAT and leads to the activation of phospholipase C gamma2. Ref.2 |
| Subunit structure | Associated with Fc receptor gamma chain. The GPVI-FcRgamma complex is associated with the Src kinase family Fyn and Lyn. |
| Subcellular location | Isoform 1: Cell membrane; Single-pass membrane protein. Isoform 2: Cell membrane; Single-pass membrane protein. |
| Tissue specificity | Megakaryocytes and platelets. Ref.2 |
| Post-translational modification | N-linked glycosylation at Asn-92 is not required for the cell surface expression, but contributes to maximal adhesion to type I collagen, collagen-related peptide (CRP), and, to a lesser extent, to the snake venom C-type lectin convulxin (CVX). |
| Involvement in disease | Bleeding disorder, platelet-type 11 (BDPLT11) [MIM:614201]: A mild to moderate bleeding disorder caused by defective platelet activation and aggregation in response to collagen. |
| Sequence similarities | Contains 2 Ig-like C2-type (immunoglobulin-like) domains. |
Ontologies
| Keywords | |
|---|---|
| Biological process | Blood coagulation Hemostasis |
| Cellular component | Cell membrane Membrane |
| Coding sequence diversity | Alternative splicing Polymorphism |
| Disease | Disease mutation |
| Domain | Immunoglobulin domain Repeat Signal Transmembrane Transmembrane helix |
| Molecular function | Receptor |
| PTM | Disulfide bond Glycoprotein |
| Technical term | 3D-structure Complete proteome Direct protein sequencing Reference proteome |
| Gene Ontology (GO) | |
| Biological_process | enzyme linked receptor protein signaling pathway Traceable author statement PubMed 9153205. Source: ProtInc leukocyte migrationTraceable author statement. Source: Reactome platelet activationNon-traceable author statement Ref.1. Source: UniProtKB |
| Cellular_component | integral to plasma membrane Traceable author statement PubMed 10822077. Source: ProtInc |
| Molecular_function | collagen binding Traceable author statement Ref.1. Source: UniProtKB transmembrane signaling receptor activityTraceable author statement PubMed 10822077. Source: ProtInc |
| Complete GO annotation... | |
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| LYN | P07948 | 2 | EBI-515278,EBI-79452 |
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q9HCN6-1) Also known as: VI-1; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q9HCN6-2) Also known as: VI-2; The sequence of this isoform differs from the canonical sequence as follows: 204-221: Missing. | ||||||
| Isoform 3 (identifier: Q9HCN6-3) Also known as: VI-3; The sequence of this isoform differs from the canonical sequence as follows: 260-339: PARQYYTKGN...QDVHSRGLCS → ESCPPVLHQG...TGMNMSITLI | ||||||
| Note: Has no transmembrane domain. Does not interact with Fc receptor gamma chain. Does not bind to collagen-like peptides. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | |||||||||||||||||||||||||||||||||||
Molecule processing | ||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 20 | 20 | Potential | |||||||||||||||||||||||||||||||||||||
| Chain | 21 – 339 | 319 | Platelet glycoprotein VI | PRO_0000232383 | ||||||||||||||||||||||||||||||||||||
Regions | ||||||||||||||||||||||||||||||||||||||||
| Topological domain | 21 – 267 | 247 | Extracellular Potential | |||||||||||||||||||||||||||||||||||||
| Transmembrane | 268 – 288 | 21 | Helical; Potential | |||||||||||||||||||||||||||||||||||||
| Topological domain | 289 – 339 | 51 | Cytoplasmic Potential | |||||||||||||||||||||||||||||||||||||
| Domain | 26 – 104 | 79 | Ig-like C2-type 1 | |||||||||||||||||||||||||||||||||||||
| Domain | 114 – 196 | 83 | Ig-like C2-type 2 | |||||||||||||||||||||||||||||||||||||
Amino acid modifications | ||||||||||||||||||||||||||||||||||||||||
| Glycosylation | 92 | 1 | N-linked (GlcNAc...) Ref.7 | |||||||||||||||||||||||||||||||||||||
| Disulfide bond | 48 ↔ 88 | Ref.9 | ||||||||||||||||||||||||||||||||||||||
| Disulfide bond | 134 ↔ 180 | Ref.9 | ||||||||||||||||||||||||||||||||||||||
Natural variations | ||||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 204 – 221 | 18 | Missing in isoform 2. | VSP_017879 | ||||||||||||||||||||||||||||||||||||
| Alternative sequence | 260 – 339 | 80 | PARQY…RGLCS → ESCPPVLHQGQPGPDMPRGC DPNNPGGVSGRGLAQPEEAP AAQGQGCAEAASAPPAPPAD PEIKRGSGWRPTGCSQPRVM FMTAEPQARSYPREGSWHGR RLKDWRVWSVEAGGQRLQLW KRGHAASSWCSIREPFGQCL SVCLPLCLRAPSIWDGRNLW RPHPPPCTLWMTWYPGWTTY WPLSSTSLIWAPDGSLRFPA LRVDSVPSSVQNPPVLPFGP LCSCLVFPRNSHPHSISHCG LTNLLSSLRTGLAGSLGMSF IFLSVKLARCPLPFTLENKI SLCNMVKPHLYQQNKKTQKL ARCGGASLYSQQLRGLRWEN GLSLGGRGCSELRSHHCTLA RVTKPDFVSKNTGMNMSITL I in isoform 3. | VSP_017880 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 58 | 1 | R → C in BDPLT11; results in abnormal protein migration and a loss of collagen binding. Ref.10 | VAR_066590 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 175 | 1 | S → N in BDPLT11; shows strongly reduced membrane expression and decreased interaction with the snake toxin convulxin. Ref.11 | VAR_066591 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 219 | 1 | P → S. Ref.1 Ref.3 Ref.5 Corresponds to variant rs1613662 [ dbSNP | Ensembl ]. | VAR_060352 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 237 | 1 | E → K. Ref.1 Ref.3 Ref.5 Corresponds to variant rs1654416 [ dbSNP | Ensembl ]. | VAR_060353 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 249 | 1 | A → T. Ref.1 Ref.3 Ref.5 Corresponds to variant rs2304167 [ dbSNP | Ensembl ]. | VAR_060354 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 317 | 1 | L → Q. Ref.1 Ref.3 Ref.5 Corresponds to variant rs1654413 [ dbSNP | Ensembl ]. | VAR_059389 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 322 | 1 | N → H. Ref.1 Ref.3 Ref.5 Corresponds to variant rs1671152 [ dbSNP | Ensembl ]. | VAR_059390 | ||||||||||||||||||||||||||||||||||||
| Natural variant | 335 | 1 | R → G. Corresponds to variant rs1654412 [ dbSNP | Ensembl ]. | VAR_060355 | ||||||||||||||||||||||||||||||||||||
Experimental info | ||||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 61 | 1 | K → A: Increases collagen binding. Ref.8 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 79 | 1 | K → E: Dramatically reduces collagen binding. Ref.8 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 80 | 1 | R → A: Reduces collagen binding. Ref.8 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 92 | 1 | N → A: Reduces collagen binding (65 to 70%). Ref.7 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 94 | 1 | S → A: Reduces collagen binding (65 to 70%). Ref.7 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 95 | 1 | L → H: No effect on collagen binding. Ref.7 | |||||||||||||||||||||||||||||||||||||
| Mutagenesis | 186 | 1 | R → A: Reduces collagen binding. Ref.8 | |||||||||||||||||||||||||||||||||||||
| Isoform 3: | ||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 314 | 1 | P → A in BAB12247. Ref.1 | |||||||||||||||||||||||||||||||||||||
| Sequence conflict | 323 | 1 | K → T in BAB12247. Ref.1 | |||||||||||||||||||||||||||||||||||||
| Sequence conflict | 573 | 1 | R → G in BAB12247. Ref.1 | |||||||||||||||||||||||||||||||||||||
| Sequence conflict | 606 | 1 | F → L in BAB12247. Ref.1 | |||||||||||||||||||||||||||||||||||||
Secondary structure | ||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | ||||||||||||||||||||||||||||||||||||||||
| Beta strand | 29 – 34 | 6 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 36 – 39 | 4 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 44 – 49 | 6 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 55 – 61 | 7 | ||||||||||||||||||||||||||||||||||||||
| Turn | 62 – 64 | 3 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 67 – 77 | 11 | ||||||||||||||||||||||||||||||||||||||
| Helix | 80 – 82 | 3 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 84 – 92 | 9 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 95 – 97 | 3 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 103 – 111 | 9 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 115 – 119 | 5 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 130 – 135 | 6 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 142 – 147 | 6 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 159 – 170 | 12 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 175 – 183 | 9 | ||||||||||||||||||||||||||||||||||||||
| Beta strand | 198 – 202 | 5 | ||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Molecular cloning, genomic structure, chromosomal localization, and alternative splice forms of the platelet collagen receptor glycoprotein VI." Ezumi Y., Uchiyama T., Takayama H. Biochem. Biophys. Res. Commun. 277:27-36(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), PROTEIN SEQUENCE OF 28-41; 62-79 AND 114-142, VARIANTS SER-219; LYS-237; THR-249; GLN-317 AND HIS-322. |
| [2] | "Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily." Jandrot-Perrus M., Busfield S., Lagrue A.-H., Xiong X., Debili N., Chickering T., Le Couedic J.-P., Goodearl A., Dussault B., Fraser C., Vainchenker W., Villeval J.-L. Blood 96:1798-1807(2000) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH FC RECEPTOR GAMMA CHAIN, TISSUE SPECIFICITY. Tissue: Megakaryocyte. |
| [3] | "Platelet glycoprotein VI." Miura Y. Submitted (NOV-1999) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS SER-219; LYS-237; THR-249; GLN-317 AND HIS-322. |
| [4] | "The DNA sequence and biology of human chromosome 19." Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S., Carrano A.V. Lucas S.M.Nature 428:529-535(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. |
| [5] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), VARIANTS SER-219; LYS-237; THR-249; GLN-317 AND HIS-322. |
| [6] | "A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets." Tsuji M., Ezumi Y., Arai M., Takayama H. J. Biol. Chem. 272:23528-23531(1997) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH FC RECEPTOR GAMMA CHAIN. |
| [7] | "The influence of N-linked glycosylation on the function of platelet glycoprotein VI." Kunicki T.J., Cheli Y., Moroi M., Furihata K. Blood 106:2744-2749(2005) [PubMed] [Europe PMC] [Abstract] Cited for: GLYCOSYLATION AT ASN-92, MUTAGENESIS OF ASN-92; SER-94 AND LEU-95. |
| [8] | "Gain- and loss-of-function mutants confirm the importance of apical residues to the primary interaction of human glycoprotein VI with collagen." O'connor M.N., Smethurst P.A., Farndale R.W., Ouwehand W.H. J. Thromb. Haemost. 4:869-873(2006) [PubMed] [Europe PMC] [Abstract] Cited for: MUTAGENESIS OF LYS-61; LYS-79; ARG-80 AND ARG-186. |
| [9] | "Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI." Horii K., Kahn M.L., Herr A.B. Blood 108:936-942(2006) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 21-203, DISULFIDE BONDS. |
| [10] | "Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations." Dumont B., Lasne D., Rothschild C., Bouabdelli M., Ollivier V., Oudin C., Ajzenberg N., Grandchamp B., Jandrot-Perrus M. Blood 114:1900-1903(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT BDPLT11 CYS-58, CHARACTERIZATION OF VARIANT BDPLT11 CYS-58. |
| [11] | "A compound heterozygous mutation in glycoprotein VI in a patient with a bleeding disorder." Hermans C., Wittevrongel C., Thys C., Smethurst P.A., Van Geet C., Freson K. J. Thromb. Haemost. 7:1356-1363(2009) [PubMed] [Europe PMC] [Abstract] Cited for: VARIANT BDPLT11 ASN-175, CHARACTERIZATION OF VARIANT BDPLT11 ASN-175. |
| + | Additional computationally mapped references. |
Cross-references
Entry information
| Entry name | GPVI_HUMAN | ||||||||
| Accession | Primary (citable) accession number: Q9HCN6 Secondary accession number(s): Q9HCN7, Q9UIF2 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
| Disclaimer | Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. It is not in any way intended to be used as a substitute for professional medical advice, diagnosis, treatment or care. | ||||||||
Relevant documents
| Human chromosome 19 Human chromosome 19: entries, gene names and cross-references to MIM |
| Human entries with polymorphisms or disease mutations List of human entries with polymorphisms or disease mutations |
| Human polymorphisms and disease mutations Index of human polymorphisms and disease mutations |
| MIM cross-references Online Mendelian Inheritance in Man (MIM) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
